contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


release-date-of-annual-report-2023-for-alk-and-webcast

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.


ALK-Abelló

On Thursday, 8 February 2024 in the afternoon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors...

On Thursday, 8 February 2024 in the afternoon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors that day at 4.00pm (CET) at which Management will review the financial results, the outlook and answer questions. The meeting will be webcast live on our website <a href="https://www.globenewswire.com/Tracker?data=vD6ttuUqSst6m4Y-WEI3ykc1qtJCn3zWgpsjZtNMKkgYaSEJzcfEjwDVDQTZMwpDEFnny02GLpC2vgtJ6twTfg==">https://ir.alk.net</a>, where the related presentation will be available shortly before the meeting begins. To register for the conference call, please use this link <a href="https://www.globenewswire.com/Tracker?data=vD6ttuUqSst6m4Y-WEI3yj5wy_--DXr19PwtNyVYzfLY0r_48T8qHOhlK7ZSEEVRY4luHyAQG86fX09IYGfJtbJiEgZgOQmO7ExDiAXoTW9lehRAdK8RVlG_Bybm-5KJSLTx23tv9SZwSdIDY-7MoQ==">https://dpregister.com/sreg/10185513/fb5a5565cd</a> and follow the instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist <a href="https://www.globenewswire.com/Tracker?data=sBcn6kjNyRY62Af_-ayELtEmk8DX43NiBAAapoRMilZwWx6dTaHhqPvwu9nh8JsQzo4MC1EGqhL9z6zg4Qoro78dt8lpzF15tcO9bEDcecVF-CIuth_EZJMOXRunwbTA">diamondpass@choruscall.com</a> and/or check your spam filter. We advise you to register on the day before the call at the latest. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/3d9cb3a0-617e-45e4-a1a6-88ad256fe237">InvestorNews_31Jan24</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDkxMTI2MSM0MDE3NTEzNTAjMjAwMjIzMQ=="> <img src="https://ml-eu.globenewswire.com/media/Mjg0NGI5YjctOGYzNC00NDIzLTk4NjEtYmM1MDc4ZWIyMzBiLTEwMTM4MDQ=/tiny/ALK-Abello.png">